e-learning
resources
Vienna 2012
Wednesday, 05.09.2012
Interstitial lung disease: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice
I. Maillet, V. Quesniaux, L. Wollin, B. Ryffel (Orleans, France; Biberach, Germany)
Source:
Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Session:
Interstitial lung disease: from bench to bedside
Session type:
Oral Presentation
Number:
4531
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Maillet, V. Quesniaux, L. Wollin, B. Ryffel (Orleans, France; Biberach, Germany). Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice. Eur Respir J 2012; 40: Suppl. 56, 4531
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Enhanced lung inflammatory response to intratracheal CpG-ODN in mice with bleomycin-induced lung fibrosis
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011
Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Effect of curcumin on inflammation in experimental pulmonary fibrosis
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2002; 20: Suppl. 38, 487s
Year: 2002
PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010
Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats
Source: Eur Respir J 2001; 17: 1228-1235
Year: 2001
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
The effect of pravastatin on bleomycin-induced lung injury and fibrosis in mouse
Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis
Year: 2010
Rikkunshito ameliorates bleomycin-induced lung injury in mice
Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation
Year: 2012
The role of expression of TLR 4 in bleomycin-induced pulmonary fibrosis in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Year: 2012
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Ghrelin ameliorates bleomycin-induced acute lung injury by protecting alveolar epithelial cells and suppressing lung inflammation
Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation
Year: 2012
Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation
versus
fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 396s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept